

FORM PTO-1083
Mail Stop: Amendment
COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, VA 22313-1450



Docket No.: 200.1133CON
Date: May 15, 2007

In re application of: Benjamin Oshlack, et al.
Serial No.: 10/689,866
Filed: October 21, 2003
For: **TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS**

Sir:

Transmitted herewith is a **Supplemental Information Disclosure Statement (5 pages)** in the above-identified application.


- ☐ Small entity status under 37 C.F.R. 1.9 and 1.27 has been previously established.
- ☐ Applicants assert small entity status under 37 C.F.R. 1.9 and 1.27.
- ☒ No fee for additional claims is required.
- ☐ A filing fee for additional claims calculated as shown below, is required:

- ☒ Also transmitted herewith are:
 - ☐ Petition for extension under 37 C.F.R. 1.136
 - ☒ Other: **Form PTO-1449** (20 pages)

- ☒ Check(s) in the amount of **\$180.00** is/are attached to cover:
 - ☐ Basic filing fee
 - ☐ Petition fee under 37 C.F.R. 1.136
 - ☒ Other: Information Disclosure Statement Fee

- ☐ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-0552.

- ☐ Any filing fee under 37 C.F.R. 1.16 for the presentation of additional claims which are not paid by check submitted herewith.
- ☐ Any patent application processing fees under 37 C.F.R. 1.17.
- ☐ Any petition fees for extension under 37 C.F.R. 1.136 which are not paid by check submitted herewith, and it is hereby requested that this be a petition for an automatic extension of time under 37 CFR 1.136.


Robert J. Paradiso, Reg. No. 41,240
DAVIDSON, DAVIDSON & KAPPEL, LLC
485 Seventh Avenue, 14th Floor
New York, New York 10018
Tel: (212) 736-1940
Fax: (212) 736-2427

I hereby certify that this correspondence and/or documents referred to as attached therein and/or fee are being deposited with the United States Postal Service with sufficient postage as "first class mail" in an envelope addressed to Mail Stop: Amendment Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on May 15, 2007.
DAVIDSON, DAVIDSON & KAPPEL, LLC

BY:


Tori Joseph



UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Humera N. Sheikh	Art Unit: 1615
Re: Application of:	Benjamin OSHLACK, et al.
Serial No.:	10/689,866
Filed:	October 21, 2003
For:	TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

May 15, 2007

S i r:

In accordance with Applicant's duty of disclosure under 37 C.F.R. § 1.56 and the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants hereby make of record the documents listed on the accompanying Form PTO-1449 (20 pages) for consideration by the Examiner in connection with the examination of the above-identified patent application.

If it is determined that any of the foreign patents or non-patent references listed on the attached Form PTO-1449 were not made of record in the parent application, the Examiner is requested to contact the undersigned so copies may be forwarded.

It is respectfully requested that the reference listed on the accompanying Form PTO-1449 (20 sheets) be made of record.

05/21/2007 SFELEKE1 00000004 10689866

01 FC:1806

180.00 0P

Applicants also respectfully advise the Examiner of the following issued U.S. patents and co-pending U.S. patent applications which are commonly assigned to the owners of the instant application:

U.S. Patent Application Serial No. 10/244,783, "OPIOID AGONIST/ANTAGONIST COMBINATIONS", filed September 16, 2002, now U.S. Patent No. 6,696,066, which is a continuation application of U.S. Patent Application Serial No. 09/815,167, "OPIOID AGONIST/ANTAGONIST COMBINATIONS", filed March 22, 2001, now U.S. Patent No. 6,475,494, issued on November 5, 2002, which is a continuation application of U.S. Patent Application Serial No. 09/218,662, "OPIOID AGONIST/ANTAGONIST COMBINATIONS", filed December 22, 1998, now U.S. Patent No. 6,277,384, issued on August 21, 2001;

U.S. Patent Application Serial No. 09/992,936, "OPIOID AGONIST/OPIOID ANTAGONIST/ACETAMINOPHEN COMBINATIONS", filed November 5, 2001, published as US 2002-0058673, which is a continuation application of U.S. Patent Application Serial No. 09/503,020, "OPIOID AGONIST/OPIOID ANTAGONIST/ACETAMINOPHEN COMBINATIONS", filed February 11, 2002, now U.S. Patent No. 6,375,957, issued on April 23, 2002, which is a continuation-in-part of U.S. Patent Application Serial No. 09/218,662, "OPIOID AGONIST/ANTAGONIST COMBINATIONS", filed December 22, 1998, now U.S. Patent No. 6,277,384, issued on August 21, 2001;

U.S. Patent Application Serial No. 09/815,162, "METHOD OF PREVENTING ABUSE OF OPIOID DOSAGE FORMS", filed March 22, 2001, now U.S. Patent No. 6,627,635, which is a continuation application of U.S. Patent Application Serial No. 09/218,663, "METHOD OF PREVENTING ABUSE OF OPIOID DOSAGE FORMS", filed December 22, 1998, now U.S. Patent No. 6,228,863, issued on May 8, 2001;

U.S. Patent Application Serial No. 09/781,076, "CONTROLLED-RELEASE COMPOSITIONS CONTAINING OPIOID AGONIST AND ANTAGONIST", filed February 8, 2001, now U.S. Patent No. 6,716,449, issued April 6, 2004;

U.S. Patent Application Serial No. 10/199,972, "PHARMACEUTICAL COMBINATIONS OF OXYCODONE AND NALOXONE", filed July 18, 2002, published as US 2003-0069263, pending;

U.S. Patent Application Serial No. 10/213,919, "OPIOID AGONIST FORMULATIONS WITH RELEASABLE AND SEQUESTERED ANTAGONIST", filed August 6, 2002, published as US 2003-0073714, pending;

U.S. Patent Application Serial No. 10/213,921, "PHARMACEUTICAL FORMULATION CONTAINING OPIOID AGONIST, OPIOID ANTAGONIST AND BITTERING AGENT", filed August 6, 2002, now U.S. Patent No. 7,144,587, issued December 5, 2006;

U.S. Patent Application Serial No. 10/214,409, "PHARMACEUTICAL FORMULATION CONTAINING OPIOID AGONIST, OPIOID ANTAGONIST, AND IRRITANT", filed August 6, 2002, published as US 2003-0068392, pending;

U.S. Patent Application Serial No. 10/214,413, "PHARMACEUTICAL FORMULATION CONTAINING OPIOID AGONIST, OPIOID ANTAGONIST AND GELLING AGENT", filed August 6, 2002, published as US 2003-0068371, pending;

U.S. Application Serial No. 10/701,041, filed November 4, 2003, published as US 2005-0095291; U.S. Application Serial No. 10/700,861 filed November 4, 2003, published as US 2005-0181046; U.S. Application Serial No. 10/700,893 filed November 4, 2003, published as US 2004-0092542; and U.S. Application Serial No. 10/700,906 filed November 4, 2003, published as US 2006-0039970, which are all continuations of

the parent application, U.S. Application Serial No. 09/781,081, entitled "Tamper-Resistant Oral Opioid Agonist Formulations", now U.S. Patent No. 6,696,088.

The Examiner's attention is also directed to the following references which were cited in the parent application, U.S. Application Serial No. 09/781,081, now U.S. Patent No. 6,696,088:

- U.S. Patent No. 6,228,863 listed as reference "TA" on the accompanying PTO-1449; and
- U.S. Patent No. 6,277,384, listed as reference "TB" on the accompanying PTO-1449;


and the following references which were cited in co-pending application no. 10/700,893, published as US 2004-0092542:

- U.S. Patent No. 6,004,970 listed as reference "SG" on the accompanying PTO-1449;
- U.S. Patent No. 6,120,806 listed as reference "SH" on the accompanying PTO-1449;
- U.S. Patent No. 6,228,863 listed as reference "TA" on the accompanying PTO-1449; and
- U.S. Patent No. 4,987,136 listed as reference "FA" on the accompanying PTO-1449.


This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) before the mailing of a Final Office Action. Accordingly, a fee in the amount of \$180.00 is enclosed. If it is determined that any additional fee is due or overpayment made, the Examiner is authorized to charge said fee or credit such overpayment to Attorney Deposit Account No. 50-0552.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By: 
Robert J. Paradiso
Reg. No. 41,240

Davidson, Davidson & Kappel, LLC
485 Seventh Avenue, 14th Floor
New York, New York 10018
(212) 736-1940

FORM PTO 1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.			
				FILING DATE: October 21, 2003		GROUP: 1615	

U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	3	9	6	5	2	5	6	06/22/1976	Leslie	424	22	
	AB	4	2	3	7	1	4	0	12/02/1980	Dudzinski	424	260	
	AC	4	3	6	6	3	1	0	12/28/1982	Leslie	536	56	
	AD	4	4	4	3	4	2	8	04/17/1984	Oshlack, et al.	424	22	
	AE	4	8	2	8	8	3	6	05/09/1989	Elger, et al.	424	419	
	AF	4	8	3	4	9	6	5	05/30/1989	Martani, et al.	424	488	
	AG	4	8	3	4	9	8	4	05/30/1989	Goldie, et al.	424	488	
	AH	4	8	3	4	9	8	5	05/30/1989	Elger, et al.	424	488	
	AI	4	8	4	4	9	0	7	07/04/1989	Elger, et al.	424	465	
	AJ	4	8	4	4	9	0	9	07/04/1989	Goldie, et al.	424	480	

FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	AK	0	1	9	3	3	5	5	09/03/1986	Europe (A3)	A61K	31/615		
	AL	0	3	1	9	2	4	3	06/07/1989	Europe (A1)	A61K	31/485		
	AM	0	3	1	9	2	4	3	11/07/1990	Europe (A2)	A61K	31/485		
	AN	0	0	0	1	3	7	7	01/13/2000	WO	A61K	31/00		
	AO	9	0	0	4	9	6	5	05/17/1990	WO	A61K	31/485		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AP	Translation of previously submitted German patent application DE 43 25 465
	AQ	Alvarez-Fuentes, et al., "Effectiveness of Repeated Administration of a New Oral Naltrexone Controlled-Release System on Morphine Analgesia"; J. Pharm Pharmacol (2001), 53; pg. 1201-1205
	AR	Alvarez-Fuentes, et al., "Preclinical Study of an Oral Controlled Release Naltrexone Complex in Mice"; J. Pharm Pharmacol (2000), 52; pg. 659-663

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866								
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.										
				FILING DATE: October 21, 2003		GROUP: 1615								
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL	BA	DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
		4	8	4	4	9	1	0	07/04/1989	Leslie, et al.	424	494		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
													YES	NO
	BB													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
	BC	Archer, Sydney; "Historical Perspective on the Chemistry and Development of Naltrexone"; Naltrexone: Research Monograph 28 (1980) pg. 3-9												
	BD	Baum, et al., "The Impact of the Addition of Naloxone on the Use and Abuse of Pentazocine"; Public Health Reports (1987) Vol. 102, No. 4 pg. 426-429												
	BE	Rapaka, et al., "Discovery of Novel Opioid Medications"; NIDA Research Monograph 147 (1995) pg. 53-83												
	BF	Bloom, et al., "Clinical Studies with Naloxone/Methadone in a Ratio of 1:20"; 5 th National Conference on Methadone Treatment (1973) Vol 2, pg. 1342 - 1349												
	BG	Blachly, M.D., "Naloxone in Opiate Addiction"; Current Psychiatric Therapies (1976) pg. 209-213												
	BH	Briscoe, et al., "Methoclocinnamox: Time Course of Changes in Alfentanil-Reinforced Responding in Rhesus Monkeys"; Psychopharmacology (2000) 148: pg. 393-399												
	BI	Abstract of Bromm, et al., "A Sensitive Method to Evaluate Effects of Analgesics in Man"; Meth and Find Exptl Clin Pharmacol 5 (8) (1983) pg. 545-551												
	BJ	Bullingham, et al., "Clinical Pharmacokinetics of Narcotic Agonist-Antagonist Drugs"; Clinical Pharm. (1983) 8: 332-343												
	BK	Calimlim, et al., "Effect of Naloxone on the Analgesic Activity of Methadone in a 1:10 Oral Combination"; Clin Pharmacol and Thera (1974) Vol. 15; No. 6 pg. 556-564												
	BL	Caruso, et al., "Methadone and Naloxone in Combination (Naldone®) for the Treatment of Heroin Addicts"; Bristol Laboratories, pg. 1336-1341F												
	BM	Cherny, Nathan I., "Opioid Analgesics"; Drugs (1996) May: 51 (5) pg. 713-737												
	BN	Chiang, et al., "Clinical Evaluation of a Naltrexone Sustained-Release Preparation"; Drug and Alcohol Dependence (1985) 16, pg. 1-8												
	BO	Chiang, et al., "Kinetics of a Naltrexone Sustained-Release Preparation"; Clin. Pharmacol Thera (1984) Vol. 36, No. 5, pg. 704-708												
	BP	Comer, et al., "Depot Naltrexone: Long-lasting Antagonism of the effects of heroin in humans"; Psychopharmacology (2002) 159; pg. 351-360												
	BQ	Crabtree, et al., "Review of Naltrexone, a long-acting opiate antagonist"; Clinical Pharmacy, Vol 3 (1984) pg. 273-280												
EXAMINER									DATE CONSIDERED					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866							
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.									
				FILING DATE: October 21, 2003		GROUP: 1615							
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL	CA	DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
		4	8	6	7	9	8	5	09/19/1989	Heafield, et al.	424	461	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES NO
	CB												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
	CC	Crain et al., "Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability"; Dept. Of Neuroscience, Albert Einstein College of Medicine, Pain 82 (1999) pg. 1-11											
	CD	Crain et al., "Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability"; Dept. Of Neuroscience, Albert Einstein College of Medicine, Pain 84 (2000) pg. 121-131											
	CE	Fink, et al., "Naloxone in Heroin Dependence"; Clin Pharm and Therapeutics, Vol 9, No. 5; pg. 568-577											
	CF	Fishman, et al., "Disposition of Naloxone-7,8- ³ H in Normal & Narcotic-Dependent Men"; J. of Pharm. and Experimental Therapeutics (1973) Vol 187, No. 3, pg. 575-580											
	CG	Fraser, Albert D., et al., "Clinical Toxicology of Drugs Used in the Treatment of Opiate Dependency"; Clinical Toxicology I, (1990) Vol 10, No. 2, pg. 375-386											
	CH	Freye, et al., "Effects of Tramadol and Tilidine/Naloxone on Oral-Caecal Transit & Pupillary Light Reflex"; Arzneim.-Forsch/Drug Res. 50 (I) (2000) pg. 24-30											
	CI	Fudala, et al., "Effects of Burpenorphine and Naloxone in Morphine-Stabilized Opioid Addicts"; Drug and Alcohol Dependence 50 (1998) pg. 1-8											
	CJ	Fudala, et al., "Human Pharmacology and Abuse Potential of Nalmefene"; Clin Pharm and Thera (1991) Vol 49, 3, pg. 300-306											
	CK	Gal, et al., "Prolonged Blockade of Opioid Effect with Oral Nalmefene"; Clin Pharmacol Ther. (1986) pg. 537-542											
	CL	Gerra, et al., "Clonidine and Opiate Receptor Antagonists in the Treatment of Heroin Addiction"; J. Substance Abuse Treatment (1995) Vol 12, 1, pg. 35-41											
	CM	Ghodse, et al., "Opioid analgesics and narcotic antagonists"; Side Effects of Drugs (2000) Annual 23, Ch. 8, pg. 96-113											
	CN	Glatt, William, M.D. FACP, "A New Method for Detoxifying Opioid-Dependent Patients"; J. Substance Abuse Treatment (1999) Vol 17, No 3, pg. 193-197											
	CO	Gold, et al., "Rapid Opioid Detoxification during General Anesthesia"; Anesthesiology (1999) Vol 91, No 6, 1639-1647											
	CP	Greenwald, et al., "Comparative Clinical Pharmacology of Short-Acting <i>Mu</i> Opioids in Drug Abusers"; J. Pharm. and Experimental Therapeutics (1996) Vol 277, No 3, pg. 1228-1236											
EXAMINER									DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866								
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.										
				FILING DATE: October 21, 2003		GROUP: 1615								
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL	DA	DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
		4	9	4	0	5	8	7	07/10/1990	Jenkins, et al.	424	480		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
												YES	NO	
	DB													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
	DC	Gupta, et al., "Morphine Combined with Doxapram or Naloxone"; Anaesthesia (1974) Vol 29 pg. 33-39												
	DD	Richter, et al., "Clinical Investigation on the Development of Dependence during Oral Therapy with Tramadol"; Arzneim-Forsch/Drug Res. 35 (No II) (1985) pg. 1742-1744												
	DE	Rosen, et al., "Effect of Clonidine Pretreatment on Naloxone-Precipitated Opiate Withdrawal"; J. of Pharm. and Experimental Ther. (1996) Vol 276, No 3, pg. 1128-1135												
	DF	Rosen, et al., "The effect of lamotrigine on naloxone-precipitated opiate withdrawal"; Drug and Alcohol Dependence (1998) Vol 52, pg. 173-176												
	DG	Rosen, et al., "A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal"; European J. of Pharm. (1996) Vol 307, pg. 251-257												
	DH	Schuh, et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. of Pharm. and Experimental Ther. (1996) Vol 278, 2, pg. 836-846												
	DI	Schuh, et al., "Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans"; Psychopharmacology (1999) Vol 145, pg. 162-174												
	DJ	Stevens, et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions"; Psychopharmacology (1981) Vol 75, pg. 210-211												
	DK	Stine, et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance"; Am. J. Drug Alcohol Abuse (1994) Vol 20, (4), pg. 445-458												
	DL	Stine, et al., "Use of Drug Combinations in Treatment of Opioid Withdrawal"; J. of Clinical Psych. (1992) Vol 12, No. 3, pg. 203-209												
	DM	Stoller, et al., "Effects of buprenorphine/naloxone in opioid-dependent humans"; Psychopharmacology (2001) Vol 154, pg. 230-242												
	DN	Strain, et al., "Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. of Pharm. and Experimental Ther. (1992) Vol 261, No. 3, pg. 985-993												
	DO	Strain, et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pg. 374-383												
	DP	Strain, et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. of Pharm. and Experimental Ther. (1993) Vol 267, No 2, pg. 624-634												
	DQ	Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages												
	DR	Umbricht, et al., "Naltrexone shortened opioid detoxification with buprenorphine"; Drug and Alcohol Dependence (1999) Vol 56, pg. 181-190												
EXAMINER									DATE CONSIDERED					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866							
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.									
				FILING DATE: October 21, 2003		GROUP: 1615							
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	EA	4	9	7	0	0	7	5	11/13/1990	Oshlack	424	451	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
	EB												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
	EC	Vaccarino, et al., "Endogenous Opiates: 1999"; Peptides 21 (2000) pg. 1975-2034											
	ED	Wang, et al., "Inverse agonists and neutral antagonists at μ opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence"; J. of Neurochemistry (2001) Vol 77, pg. 1590-1600											
	EE	Way, et al., "Responsivity to Naloxone during Morphine Dependence"; Annals New York Academy of Sciences, pg. 252-261											
	EF	Weinberg, et al., "Sublingual absorption of selected opioid analgesics"; Clin Pharm Ther (1988) Vol 44, No 3, pg. 335-342											
	EG	Wells, et al., "In Vivo Pharmacological Characterization of SoRI 9409, a Nonpeptidic Opioid μ -Agonists/ δ -Antagonist that Produces Limited Antinociceptive Tolerance and Attenuates Morphine Physical Dependence"; J. Pharm and Exper. Thera. (2001) Vol 297, No 2, pg. 597-605											
	EH	Wodak, Alex, "Drug Treatment for Opioid Dependence"; Australian Prescriber (2001) Vol 24, No 1, pg. 4-6											
	EI	Wright, et al., "Acute physical dependence in humans; repeated naloxone-precipitated withdrawal after a single-dose of methadone"; Drug and Alcohol Dependence (1991) Vol 27, pg. 139-148											
	EJ	Zhu, et al., "Naltrexone-precipitated morphine withdrawal in infant rat is attenuated by acute administration of NOS inhibitors but not NMDA receptor antagonists"; Psychopharmacology (2000) Vol 150, pg. 325-336											
	EK	Han, et al., "Mucoadhesive buccal disks for novel nalbuphine prodrug controlled delivery: effect of formulation variables on drug release and mucoadhesive performance"; International J. of Pharm (1999) Vol 177, pg. 201-209											
	EL	Handal, et al., "Naloxone"; Annals of Emergency Medicine (1983) Vol 12:7, pg. 438-445											
	EM	Harris, et al., "Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine"; Drug and Alcohol Dependence (2000) Vol 61, pg. 85-94											
	EN	Hawkes, et al., "Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine"; Aliment Pharm Ther (2001) Vol 15, pg. 625-630											
	EO	Högger, et al., "Comparison of tilidine/naloxone, tramadol and bromfenac in experimental pain: a double-blind randomized crossover study in healthy human volunteers"; International J. Clin Pharm and Ther (1999) Vol 37, No 8, pg. 377-385											
EXAMINER									DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866						
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)						APPLICANT(S): Oshlack, et al.								
						FILING DATE: October 21, 2003		GROUP: 1615						
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	FA	4	9	8	7	1	3	6	01/22/1991	Kreek, et al.	514	282		
	FB	4	9	9	0	3	4	1	02/05/1991	Goldie, et al.	424	484		
	FC	5	0	7	1	6	4	6	12/10/1991	Malkowska, et al.	424	497		
	FD	5	0	9	1	1	8	9	02/25/1992	Heafield, et al.	424	457		
	FE	5	2	1	5	7	5	8	06/01/1993	Krishnamurthy	424	488		
	FF	5	2	2	6	3	3	1	07/13/1993	Thompson, et al.	73	865.9		
	FG	5	2	6	6	3	3	1	11/30/1993	Oshlack, et al.	424	468		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	FH													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
	FI	Budd, Keith, "Clinical use of Opioid Antagonists"; Bailliere's Clinical Anesthesiology (1987) Vol 1, No 4, pg. 993-1011												
	FJ	Crain, et al., "Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment"; Proc. Natl. Acad. Sci (1995) Vol 92, pg. 10540-10544												
	FK	Howes, et al., "The Pharmacology of TR5109, a New Narcotic Agonist/Antagonist Analgesic"; NIDA Research (1979) pg. 99-105												
	FL	Leeling, et al., "Disposition and metabolism of codorphone in the rat, dog and man"; Drug Metabolism and Disposition (1982) Vol 10, No 6, pg. 649-653												
	FM	Amass, et al., "Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet"; Drug and Alcohol Dependence (2000) Vol 58, pg. 143-152												
	FN	Hussain, et al., "Buccal and oral bioavailability of naloxone and naltrexone in rats"; (1987) Vol 36, pg. 127-130												
	FO	Jasinski, et al., "The human pharmacology and abuse potential of N-allylnoroxymorphone naloxone"; J. of Pharm and Exper Thera (1967) Vol 157, No. 2, pg. 420-426												
	FP	Jones, et al., "Nalmefene: blockade of intravenous morphine challenge effects in opioid abusing humans"; Drug and Alcohol Dependence (2000) Vol 60, pg. 29-37												
	FQ	Kanof, et al., "Clinical Characteristics of Naloxone-Precipitated Withdrawal in Human Opioid-Dependent Subjects"; J. of Pharm and Exper Thera (1992) Vol 260, No. 1, pg. 355-363												
	FR	King, et al., "Naltrexone Biotransformation and Incidence of Subjective Side Effects: A Preliminary Study"; Alcoholism: Clin and Exp Res (1997) Vol 21, No. 5, pg. 906-909												
EXAMINER										DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866						
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)						APPLICANT(S): Oshlack, et al.								
						FILING DATE: October 21, 2003		GROUP: 1615						
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL	GA	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	GA	5	2	8	6	4	9	3	02/15/1994	Oshlack, et al.	424	468		
	GB	5	3	2	4	3	5	1	06/28/1994	Oshlack, et al.	106	153		
	GC	5	3	3	6	6	9	1	08/09/1994	Raffa, et al.	514	629		
	GD	5	3	5	6	4	6	7	10/18/1994	Oshlack, et al.	106	153		
	GE	5	4	1	1	7	4	5	05/02/1995	Oshlack, et al.	424	456		
	GF	5	4	6	0	8	2	6	10/24/1995	Merrill, et al.	424	470		
	GG	5	4	7	2	7	1	2	12/05/1995	Oshlack, et al.	424	480		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	GH	8	7	0	1	2	8	2	03/12/1987	WO	A61K	31/485		
	GI	0	1	3	2	1	8	0	05/10/2001	WO (A2)	A61K	31/485		
	GJ	0	1	6	8	0	8	0	09/20/2001	WO (A2)	A61K	31/00		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
	GK	Kogan, et al., "Estimation of the Systemic Availability and other Pharmacokinetic Parameters of Naltrexone in Man after Acute and Chronic Oral Administration"; Res. Comm. in Chem. Path. and Pharm (1977) Vol 18, No. 1, pg. 29-34												
	GL	Kosten, Thomas R., M.D., "Buprenorphine for Benzodiazepine-Abusing Heroin Addicts"; Amer J. of Psychiatry (1994) Vol 1, pg. 151												
	GM	Kosten, et al., "Opioid antagonist challenges in buprenorphine maintained patients"; Drug and Alcohol Dependence (1990) Vol 25, pg. 73-78												
	GN	Kurland, et al., "Naloxone and the Narcotic Abuser: A Controlled Study of Partial Blockade"; Inter. J. of the Addictions (1974) Vol 9, No. 5, pg. 663-672												
	GO	Lee, et al., "Nalbuphine Coadministered with Morphine Prevents Tolerance and Dependence"; Anesth Analg (1997) Vol 84, pg. 810-815												
	GP	Lehmann, et al., "Influence of Naloxone on the Postoperative Analgesic and Respiratory Effects of Buprenorphine"; Eur J. Clin. Pharm. (1988) Vol 34, 343-352												
	GQ	Levine, et al., "Potentiation of Pentazocine Analgesia by Low-dose Naloxone"; J Clin Invest. (1988) Vol 82, pg. 1574 - 1577												
EXAMINER										DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866							
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.									
				FILING DATE: October 21, 2003		GROUP: 1615							
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	HA	5	4	7	8	5	7	7	12/26/1995	Sackler, et al.	424	489	
	HB	5	5	0	0	2	2	7	03/19/1996	Oshlack, et al.	424	476	
	HC	5	5	0	8	0	4	2	04/16/1996	Oshlack, et al.	424	468	
	HD	5	5	0	8	0	4	3	04/16/1996	Krishnamurthy	424	484	
	HE	5	5	4	9	9	1	2	08/27/1996	Oshlack, et al.	424	468	
	HF	5	5	5	2	4	2	2	09/03/1996	Gauthier, et al.	514	368	
	HG	5	5	9	1	4	5	2	01/07/1997	Miller, et al.	424	468	
	HH	5	6	0	1	8	4	5	02/11/1997	Buxton, et al.	424	495	
	HI	5	6	2	2	7	2	2	04/22/1997	Knott, et al.	424	494	
	HJ	5	6	3	9	4	7	6	06/17/1997	Oshlack, et al.	424	468	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
	HK												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
	HL	Loimer, et al., "Combined Naloxone/Methadone Preparations for Opiate Substitution Therapy"; J. of Substance Abuse Treatment (1991) Vol 8, pg. 157-160											
	HM	Martin, et al., "Bioavailability Investigation of a New Tilidine/Naloxone Liquid Formulation Compared to a Reference Formulation"; Arzneim.-Forsch./Drug Res. (1999) Vol 49, pg. 599-607											
	HN	Martin, et al., "Demonstration of Tolerance to and Physical Dependence on N-allylnormorphine (Nalorphine)"; J. of Pharm and Exper Thera (1965) Vol 150, No. 3, pg. 437-442											
	HO	Mendelson, et al., "Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers"; Psychopharmacology (1999) Vol 141, pg. 37-46											
	HP	Mendelson, et al., "Buprenorphine and Naloxone Interactions in Methadone Maintenance Patients"; Society of Biological Psychiatry (1997) Vol 41, pg. 1095-1101											
	HQ	Nutt, et al., "Methadone-naloxone mixtures for use in methadone maintenance programs"; Clin Pharma and Thera, Vol 15, No. 2, pg. 156-166											
	HR	Parwatikar, et al., "Methadone-naloxone in combination for the treatment of heroin addicts"; Clin Pharm and Thera, Vol 14, No. 6, pg. 941-948											
EXAMINER									DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866							
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.									
				FILING DATE: October 21, 2003		GROUP: 1615							
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	IA	5	6	5	6	2	9	5	08/12/1997	Oshlack, et al.	424	468	
	IB	5	6	7	0	1	7	2	09/23/1997	Buxton, et al.	424	495	
	IC	5	6	7	2	3	6	0	09/30/1997	Sackler, et al.	424	490	
	ID	5	6	8	1	5	8	5	10/28/1997	Oshlack, et al.	424	494	
	IE	5	7	6	3	4	5	2	06/09/1998	Miller, et al.	514	282	
	IF	5	7	8	0	4	7	9	07/14/1998	Kim	514	282	
	IG	5	8	1	1	1	2	6	09/22/1998	Krishnamurthy	424	498	
	IH	5	8	3	4	4	7	7	11/10/1998	Mioduszewski	514	282	
	II	5	8	4	3	4	8	0	12/01/1998	Miller, et al.	424	484	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
	IJ												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
	IK	Parwartikar, et al., "Naloxone-Methadone Combination for the Treatment of Opiate Dependence"; Missouri Institute of Psychiatry, pg. 1350-1354											
	IL	Pitts, et al., "Antinociceptive and Response Rate-Altering Effects of <i>Kappa</i> Opioid Agonists, Spiradoline, Enadoline and U69,593, Alone and in combination with Opioid Antagonists in Squirrel Monkeys"; J. Pharm and Exper Thera (1994) Vol 271, No. 3, pg. 1501-1508											
	IM	Preston, et al., "Buprenorphine and Naloxone alone and in combination in opioid-dependent humans"; Psychopharmacology (1988) Vol 94, pg. 484-490											
	IN	Preston, et al., "Differential Naltrexone Antagonism of Hydromorphone and Pentazocine Effects in Human Volunteers"; J. Pharm and Exper Thera (1993) Vol 264, No. 2, pg. 813-823											
	IO	Preston, et al., "Effects of Sublingually given naloxone in opioid-dependent human volunteers"; Drug and Alcohol Dependence (1990) Vol 25, pg. 27-34											
	IP	Bigelow, et al., "Abuse Liability Assessment of Buprenorphine-Naloxone Combinations"; Dept. of Psychiatry and Behavioral Sciences - The Johns Hopkins University School of Medicine, pg. 145-149											
	IQ	Wikler, et al., 'N-Allylnormorphine: Effects of single doses and precipitation of acute "Abstinence Syndromes" during addiction to morphine, methadone or heroin in man (post-addicts)'; N-Allylnormorphine During Narcotic Addiction (1953) pg. 8-20											
EXAMINER									DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866						
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)						APPLICANT(S): Oshlack, et al.								
						FILING DATE: October 21, 2003		GROUP: 1615						
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	JA	5	8	4	9	2	4	0	12/15/1998	Miller, et al.	264	460		
	JB	5	8	6	9	0	9	7	02/09/1999	Wong, et al.	424	473		
	JC	5	8	7	9	7	0	5	03/09/1999	Heafield, et al.	424	464		
	JD	5	8	9	1	4	7	1	04/06/1999	Miller, et al.	424	468		
	JE	5	9	0	8	8	4	8	06/01/1999	Miller, et al.	514	282		
	JF	5	9	5	8	4	5	2	09/28/1999	Oshlack, et al.	424	457		
	JG	5	9	5	8	4	5	9	09/28/1999	Chasin, et al.	424	490		
	JH	5	9	6	5	1	6	1	10/12/1999	Oshlack, et al.	424	457		
	JI	5	9	6	5	1	6	3	10/12/1999	Miller, et al.	424	468		
	JJ	5	9	6	8	5	5	1	10/19/1999	Oshlack, et al.	424	456		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	JK													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
	JL	Zaks, et al., "Naloxone Treatment of Opiate Dependence"; JAMA (1971) Vol 215, No. 13, pg. 2108-2110												
	JM	Barton, et al., "Intranasal Administration of Naloxone by Paramedics"; Prehospital Emergency Care (2002) Vol 6, No. 1, pg. 54-58												
	JN	Blachly, Paul, H., M.D., "Naloxone in Opiate Addiction"; Current Psychiatric Therapies (1976) pg. 209-213												
	JO	Bashaw, et al., "Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade"; Inter J. of Clin Pharm and Thera (1995) Vol 33, No. 9, 524-529												
	JP	Jasinski, D.R., "Assessment of the Abuse Potentiality of Morphinelike Drugs (Methods Used in Man)"; Drug Addiction (1977) pg. 197-258												
	JQ	Johnson, et al., "Buprenorphine and Naloxone for Heroin Dependence"; Substance Use Disorders (2000) pg. 519-526												
	JR	Strain, et al., "Opioid antagonist effects of dezocine in opioid-dependent humans"; Clin Pharm and Thera (1996) Vol 60, No. 2, pg. 206-217												
EXAMINER										DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866								
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.										
				FILING DATE: October 21, 2003		GROUP: 1615								
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	KA	6	0	2	4	9	8	2	02/15/2000	Oshlack, et al.	424	476		
	KB	6	0	6	8	8	5	5	05/30/2000	Leslie, et al.	424	468		
	KC	6	0	7	7	5	3	2	06/20/2000	Malkowska, et al.	424	457		
	KD	6	0	7	7	5	3	3	06/20/2000	Oshlack, et al.	424	461		
	KE	6	1	0	3	2	5	8	08/15/2000	Simon	424	449		
	KF	6	1	0	3	2	6	1	08/15/2001	Chasin, et al.	424	459		
	KG	6	1	4	3	3	2	2	11/07/2000	Sackler, et al.	424	459		
	KH	6	1	4	3	3	2	8	11/07/2000	Heafield, et al.	424	489		
	KI	6	1	6	2	4	6	7	12/19/2000	Miller, et al.	424	468		
	KJ	6	2	1	0	7	1	4	04/03/2001	Oshlack, et al.	424	476		
	KK	6	2	5	4	8	8	7	07/03/2001	Miller, et al.	424	468		
	KL	6	2	6	1	5	9	9	07/17/2001	Oshlack, et al.	424	457		
	KM	6	2	9	4	1	9	5	09/25/2001	Oshlack, et al.	424	457		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	KN	0	1	3	7	7	8	5	05/31/2001	WO (A2)	A61K			
	KO	0	1	5	2	8	5	1	07/26/2001	WO (A1)	A61K	31/485		
	KP	0	1	8	5	2	5	7	11/15/2001	WO (A2)	A61P			
	KQ	0	1	9	3	8	5	2	12/13/2001	WO (A2)	A61K	31/00		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
	KR	Preston, et al., "Abuse liability studies of opioid agonist-antagonists in humans"; Drug and Alcohol Dependence (1991) Vol 28, pg. 49-82												
	KS	Brennscheidt, et al., "Pharmacokinetics of Nortilidine and Naloxone after Administration of Tilidine/Naloxone Solution or Tilidine/Naloxone Sustained Release Tablets"; Arzneimittel-Forsch/Drug Res. (2000) Vol 50, pg. 1015-1022												
EXAMINER										DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866						
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)						APPLICANT(S): Oshlack, et al.								
						FILING DATE: October 21, 2003		GROUP: 1615						
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	LA	6	3	0	6	4	3	8	10/23/2001	Oshlack, et al.	424	468		
	LB	6	3	2	6	0	2	7	12/04/2001	Miller, et al.	424	468		
	LC	6	3	3	5	0	3	3	01/01/2002	Oshlack, et al.	424	457		
	LD	6	3	7	5	9	5	7	04/23/2002	Kaiko, et al.	424	400		
	LE	6	3	8	7	4	0	4	05/14/2002	Oshlack, et al.	424	480		
	LF	6	3	9	9	0	9	6	06/04/2002	Miller, et al.	424	464		
	LG	6	4	7	5	4	9	4	11/05/2002	Kaiko, et al.	424	400		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	LH													
	LI													
	LJ													
	LK													
	LL													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
	LM													
	LN													
	LO													
	LP													
EXAMINER										DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1133CONSERIAL NO.:
10/689,866**LIST OF PRIOR ART CITED BY APPLICANT**

(Use several sheets if necessary)

APPLICANT(S):
Oshlack, et al.FILING DATE:
October 21, 2003GROUP:
1615**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	MA	5	9	9	8	4	3	4	12/99	Mitch et al.	514	210.16	
	MB	5	9	7	2	9	5	4	10/99	Foss	514	282	
	MC	5	9	6	8	5	4	7	10/99	Reder et al.	424	449	
	MD	5	9	4	2	2	4	1	8/99	Chasin et al.	424	426	
	ME	5	8	8	0	1	3	2	3/99	Hill	514	282	
	MF	5	8	6	6	1	6	4	2/99	Kuczynski et al.	424	472	
	MG	5	8	6	0	9	5	0	1/99	Demopoulos et al.	604	49	
	MH	5	8	5	8	0	1	7	1/99	Demopoulos et al.	604	890.1	
	MI	5	7	6	7	1	2	5	6/98	Crain et al.	514	282	
	MJ	5	6	3	3	2	5	9	5/97	Qin et al.	514	282	
	MK	5	6	2	4	9	3	2	4/97	Qin et al.	514	282	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	ML	19	6	5	1	5	5	1	6/98	DE	A61K	31/485		
	MM	29	7	1	9	7	0	4	2/97	DE	A61K	31/485		
	MN	4	3	2	5	4	6	5	2/95	DE	A61K	31/485	X	
	MO	2	2	2	2	0	3	9	11/72	DE	A61K	27/00		
	MP	0	9	1	3	1	5	2	6/99	EP	A61K	31/485		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	MQ	Abstract, Cancer Chemother Pharmacol (1998); 42(4):287-91.											
	MR	Yuan et al., Drug and Alcohol Dependence (1998); 52:161-165.											
	MS	Gan et al., "Opioid-Sparing Effects of a Low-Dose Infusion of Naloxone in Patient-Administered Morphine Sulfate," Anesthesiology (1997), 87(5):1075-1080.											

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866								
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.										
				FILING DATE: October 21, 2003		GROUP: 1615								
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL	NA	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	5	6	1	6	6	0	1	4/97	Khanna et al.	514	399			
	NB	5	5	8	5	3	4	8	12/96	Crain et al.	514	12		
	NC	5	5	8	0	8	7	6	12/96	Crain et al.	514	282		
	ND	5	5	7	8	7	2	5	11/96	Portoghese et al.	546	35		
	NE	5	5	7	4	0	5	2	11/96	Rose et al.	514	343		
	NF	5	5	5	6	8	3	8	9/96	Mayer et al.	514	25		
	NG	5	5	3	4	4	9	2	7/96	Aston et al.	514	608		
	NH	5	5	1	4	6	8	0	5/96	Weber et al.	514	249		
	NI	5	5	1	2	5	7	8	4/96	Crain et al.	514	282		
	NJ	5	5	0	2	0	5	8	3/96	Mayer et al.	514	289		
	NK	5	4	8	6	3	6	2	1/96	Kitchell et al.	424	426		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	NL	0	6	4	7	4	4	8	4/95	EP	A61K	31/485		
	NM	0	3	5	2	3	6	1	1/90	EP	A61K	31/485		
	NN	0	2	0	5	2	8	2	12/86	EP	A61K	9/22		
	NO	9	9	3	2	1	2	0	7/99	WO	A61K	31/485		
	NP	9	8	3	5	6	7	9	8/98	WO	A61K	31/485		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
	NQ	Shen et al., "Ultra-Low Doses of Naltrexone or Etorphine Increase Morphine's Antinociceptive Potency and Attenuate Tolerance/Dependence in Mice," Brain Research (1997), 757:176-190.												
	NR	Yuan et al., Clinical Trials and Therapeutics (1997), 61:467-475.												
EXAMINER										DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1133CONSERIAL NO.:
10/689,866

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):
Oshlack, et al.FILING DATE:
October 21, 2003GROUP:
1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	OA	5	4	7	2	9	4	3	12/95	Crain et al.	514	12	
	OB	5	4	5	7	2	0	8	10/95	Portoghese et al.	546	35	
	OC	5	4	2	6	1	1	2	6/95	Zagon et al.	514	282	
	OD	5	3	7	6	6	6	2	12/94	Ockert	514	282	
	OE	5	3	5	6	9	0	0	10/94	Bihari et al.	514	282	
	OF	5	3	5	2	6	8	3	10/94	Mayer et al.	514	289	
	OG	5	3	5	2	6	8	0	10/94	Portoghese et al.	514	279	
	OH	5	3	2	1	0	1	2	6/94	Mayer et al.	514	25	
	OI	5	3	1	7	0	2	2	5/94	Borsodi et al.	514	282	
	OJ	5	3	1	6	7	5	9	5/94	Rose et al.	424	10	
	OK	5	2	7	3	7	6	0	12/93	Oshlack et al.	424	486	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	OL	9	7	3	3	5	6	6	9/97	WO	A61K	9/20		
	OM	9	6	0	2	2	5	1	2/96	WO	A61K	31/485		
	ON	9	5	0	3	8	0	4	2/95	WO	A61K	31/485		
	OO	9	4	0	6	4	2	6	3/94	WO	A61K	31/46		
	OP	8	3	0	3	1	9	7	9/83	WO	A61K	9/22		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	OQ	Mendelson J., et al, "Buprenorphine and Naloxone Interactions in Opiate-Dependent Volunteers," Clin. Phar. Ther. (1996), 60:105-114.											
	OR	Walsh et al., "Effects of Naltrexone on Response to Intravenous Cocain, Hydromorphone and their Combination in Humans," (1996).											

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1133CONSERIAL NO.:
10/689,866**LIST OF PRIOR ART CITED BY APPLICANT**

(Use several sheets if necessary)

APPLICANT(S):
Oshlack, et al.FILING DATE:
October 21, 2003GROUP:
1615**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	PA	5	2	5	6	6	6	9	10/93	Askanazi et al.	514	282	
	PB	5	2	3	6	7	1	4	8/93	Lee et al.	424	449	
	PC	5	2	2	5	4	4	0	7/93	London et al.	514	535	
	PD	5	1	4	9	5	3	8	9/92	Granger et al.	424	449	
	PE	5	1	0	2	8	8	7	4/92	Goldberg	514	282	
	PF	5	0	9	6	7	1	5	3/92	Sinclair	424	449	
	PG	5	0	8	6	0	5	8	2/92	Sinclair et al.	514	282	
	PH	5	0	7	5	3	4	1	12/91	Mendelson et al.	514	282	
	PI	4	9	3	5	4	2	8	6/90	Lewis	514	282	
	PJ	4	8	8	9	8	6	0	12/89	Rzeszotarski et al.	514	282	
	PK	4	8	8	2	3	3	5	11/89	Sinclair	514	282	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	PL													

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	PM	Chih-Cheng Chien, Neuroscience Letters 190 (1995), 137-139.
	PN	Crain et al., "Ultra-Low Concentrations of Naloxone Selectively Antagonize Excitatory Effects of Morphine on Sensory Neurons, Thereby Increasing Its Antinociceptive Potency and Attenuating Tolerance/Dependence During Chronic Cotreatment," Proc. Natl. Acad. Sci. USA (1995), 92:10540-10544.
	PO	Hanson, Analgesic, Antipyretic and Anti-Inflammatory Drugs in Remington's Science and Practice of Pharmacy (1995), 2:1207.
	PP	Physician's Desk Reference 48 th Ed. (1994) Montvale, NJ, 2120-2121.
	PQ	Foss et al., J. Clin Pharmacol (1993), 33:747-751.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866							
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.									
				FILING DATE: October 21, 2003		GROUP: 1615							
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	QA	4	8	7	3	0	7	6	10/89	Fishman et al.	412	10	
	QB	4	8	6	1	7	8	1	8/89	Goldberg	514	282	
	QC	4	8	6	1	5	9	8	8/89	Oshlack et al.			
	QD	4	8	0	6	5	5	8	2/89	Wuest et al.	514	381	
	QE	4	8	0	6	5	4	3	2/89	Choi	514	464	
	QF	4	8	0	6	3	4	1	2/89	Chien et al.	424	448	
	QG	4	8	0	3	2	0	8	2/89	Pasternak	514	282	
	QH	4	7	8	5	0	0	0	11/88	Kreek et al.	514	282	
	QI	4	7	6	9	3	7	2	9/88	Kreek et al.	514	282	
	QJ	4	7	6	0	0	6	9	7/88	Rzeszolarski et al.	514	282	
	QK	4	7	3	0	0	4	8	3/88	Portoghese et al.	546	45	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
	QL												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
	QM	Holmes et al., Anesth. Analg. (1993), 77:1166-73.											
	QN	Miaskowski et al., Brain Research (1992), 596:41-45.											
	QO	Weinhold et al., "Buprenorphine Alone and In Combination with Naltrexone in Non-Dependent Humans," Drug and Alcohol Dependence (1992), 30:263-274.											
	QP	Cappel et al., Pharma. Bioch. & Behav. (1989), 34:425-427.											
	QQ	Vaccarino et al., Pain (1989), 36:103-109.											
	QR	Gonzalez et al., "Naltrexone: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in the Management of Opioid Dependence," Drugs (1988), 35:192-213.											
EXAMINER									DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866							
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.									
				FILING DATE: October 21, 2003		GROUP: 1615							
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	RA	4	7	1	9	2	1	5	1/88	Goldberg	514	282	
	RB	4	6	6	1	4	9	2	4/87	Lewis et al.	514	282	
	RC	4	6	0	8	3	7	6	8/86	Pasternak	514	282	
	RD	4	5	8	2	8	3	5	4/86	Lewis et al.	514	282	
	RE	4	5	7	3	9	9	5	3/86	Chen et al.	604	896	
	RF	4	4	6	4	3	7	8	8/84	Hussain et al.	424	260	
	RG	4	4	5	7	9	3	3	7/84	Gordon et al.	424	260	
	RH	4	4	5	1	4	7	0	5/84	Ganti	424	260	
	RI	4	4	0	1	6	7	2	8/83	Portoghese et al.	424	260	
	RJ	4	1	7	6	1	8	6	11/79	Goldberg	424	260	
	RK	3	9	6	6	9	4	0	6/76	Pachter et al.	424	260	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
	RL												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
	RM	Sunshine, et al., "Analgesic Efficacy of Pentazocine Versus a Pentazocine-Naloxone Combination Following Oral Administration," Clin. J. Pain (1988), 4:35-40.											
	RN	Wang et al., "Crossover and Parallel Study of Oral Analgesics," J. clin. Pharmacol (1981), 21:162-168.											
	RO												
	RP												
	RQ												
	RR												
EXAMINER									DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866					
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)						APPLICANT(S): Oshlack, et al.							
						FILING DATE: October 21, 2003		GROUP: 1615					
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL	SA	DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	SA	3	8	7	9	5	5	5	4/75	Pachter et al.	424	260	
	SB	3	7	7	3	9	5	5	11/73	Pachter et al.	424	260	
	SC	3	6	7	6	5	5	7	7/72	Lachman et al.	424	260	
	SD	3	4	9	3	6	5	7	2/70	Lewenstein et al.	424	260	
	SE	3	3	3	2	9	5	0	7/67	Blumberg et al.	260	285	
	SF	2	7	7	0	5	6	9	11/56	Fromherz et al.	167	65	
	SG	6	0	0	4	9	7	0	12/99	O'Malley et al.	514	282	
	SH	6	1	2	0	8	0	6	9/00	Whitmire	424	497	
	SI	6	5	7	9	5	3	6	06/03	Hirsch et al.	424	484	
	SJ	6	6	0	8	0	7	5	08/03	Foss et al.	514	282	
	SK	6	7	1	6	4	4	9	04/04	Oshlack et al.	514	002	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES NO	
	SL												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
	SM	Benfey, Function of Myocardial α -ADRENOCEPTORS: Life Sciences (1982) Vol. 31 pg 101-112											
	SN	Levine, et al., Potentiation of Pentazocine Analgesia by Low-dose Naloxone: J. Clin. Invest. (1988) Vol. 82 pg. 1574-1577											
	SO	Yoburn, et al., Opioid Antagonist-induced Receptor Upregulation: Effects of Concurrent Agonist Administration, (1994) (Publication Date): Brain Research Bulletin, Vol. 33 pg 237-240											
	SP	Bunzow, et al., Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a μ , δ or κ opioid receptor type: FEBS Letters 347 (1994) pg. 284-288											
	SQ	Mollereau, et al., ORL1, a novel member of the opioid receptor family: Cloning, functional expression and localization: FEBS Letters 341 (1994) pg. 33-38											
	SR	Wang, et al., cDNA cloning of an orphan opiate receptor gene family member and its splice variant: FEBS Letters 348 (1994) 75-79											
	SS	Suzuki, et al., Morphine conditioned place preference after chronic treatment with naloxone in the rat: Research Communications in Substances of Abuse. (1991) Vol. 12, No. 3 pg. 119-131											
EXAMINER									DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1133CONSERIAL NO.:
10/689,866

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):
Oshlack, et al.FILING DATE:
October 21, 2003GROUP:
1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	TA	6	2	2	8	8	6	3	05/08/01	Palermo et al.	514	282	
	TB	6	2	7	7	3	8	4	08/21/01	Kaiko et al.	424	400	
	TC	6	6	2	7	6	3	5	09/03	Palermo et al.	514	282	
	TD	6	6	9	6	0	6	6	02/04	Kaiko et al.	424	400	
	TE	6	4	7	5	4	9	4	11/02	Kaiko et al.	424	400	
	TF	7	1	4	4	5	8	7	12/06	Oshlack et al.	424	490	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	TG	WO	98	2	5	6	1	3	06/18/98	EPO	A61K	31/485		X
	TH	WO	00	3	8	6	4	9	07/06/00	EPO	A61K	9/00		X

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	TI	Life Sci. 1982 31 pg 101-104											
	TJ	J Pharm. Exper. Ther. 1991 259(2) pg 582-589											
	TK	Pharmacol. Bio. Beh. 1995 51 (2) pg 535-539											
	TL	J. Clin. Invest. 1988 82(5) pg 1574-1577											
	TM	Brain Res. 2001 888 pg 75-82											
	TN	Res. Comm. Sust. Abuse 1991 12(3) pg 119-131											
	TO	Brain Res. Bull. 1994 33(2) pg 237-240											
	TP	FEBS Lett. 1994 347, pg 284-288											
	TQ	FEBS Lett. 1994 341 pg 33-38											
	TR	FEBS Lett. 1994 348 pg 75-79											
	TS	Neuroscience 1998 82, pg 223-240											
	TT	J. Neuro Sci 1998 18, pg 9685-9694											
	TU	Neurosci. Lett. 1999 272, pg 183-186											
	TV	Eur. J. Pharmacol. 2000 404, pg 153-159											

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.